apomorphine has been researched along with Abnormal Movements in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (45.83) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Larson, D; Simuni, T | 1 |
| Barbosa, P; Djamshidian, A; Lees, AJ; Warner, TT | 1 |
| Batzu, L; Bhattacharya, K; Borgohain, R; Chaudhuri, KR; Dhamija, RK; Falup-Pecurariu, C; Goyal, V; Kumar, NSS; Kumar, S; L K, P; Metta, V; Mrudula, R; Rodriguez-Blazquez, C; S, A | 1 |
| Bhargava, P; Blum, D; Espay, AJ; Factor, SA; Hauser, RA; Isaacson, S; Leinonen, M; Navia, B; Olanow, CW; Pahwa, R; Sciarappa, K; Shill, HA | 1 |
| Ares, B; Castro, A; Fernández-Pajarín, G; Rivas, MT; Sesar, Á | 1 |
| Antonini, A; Nitu, B | 1 |
| Auburger, G; Bez, F; Brehm, N; Carlsson, T; Cenci, MA; Gispert, S; Kern, B | 1 |
| Kim, JH; Lenz, FA; Liu, CC; Verhagen-Metman, L; Zhao, L | 1 |
| Poewe, W | 1 |
| Jia, J; Li, B; Liu, L; Pan, Y; Sun, Z; Wang, H; Wang, X; Yu, F; Zhang, L | 1 |
| Albanese, A; Dollenz, C; Elia, AE; Soliveri, P | 1 |
| Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C | 1 |
| Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; López-Azcárate, J; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M | 1 |
| Stocchi, F | 1 |
| CORNET, A; GRIVAUX, M; GUERRE, J; JUSTIN-BESANCON, L; TOURNEUR, R | 1 |
| PARSON, GW | 1 |
| Kang, UJ; Kim, YS; Lee, EA; Lee, WY | 1 |
| Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV | 1 |
| Bhatia, K; Evans, A; Hoffman, M; Hughes, A; Katzenschlager, R; Lees, AJ; Manson, AJ; Quinn, N; Swinn, L; Watt, H | 1 |
| Bibbiani, F; Chase, TN; Costantini, LC; Patel, R | 1 |
| Menon, R; Stacy, M | 1 |
| Marion, MH | 1 |
| de Luis, P; del Real, MA; Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Altibrandi, MG; Bassi, A; Bernardi, G; Giacomini, P; Mazzone, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
6 review(s) available for apomorphine and Abnormal Movements
| Article | Year |
|---|---|
New dopaminergic therapies for PD motor complications.
Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease | 2022 |
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Dyskinesias; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2018 |
Treatments for Parkinson disease--past achievements and current clinical needs.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic alpha-Antagonists; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Brain; Cholinesterase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Dyskinesias; Excitatory Amino Acid Antagonists; History, 20th Century; Humans; Levodopa; Parkinson Disease; Serotonin Agents | 2009 |
Prevention and treatment of motor fluctuations.
Topics: Antiparkinson Agents; Apomorphine; Benzophenones; Dyskinesias; Enzyme Inhibitors; Humans; Levodopa; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
Apomorphine in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Contraindications; Drug Administration Routes; Dyskinesias; Humans; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2007 |
[Drug treatments and motor complications in advanced stage Parkinson's disease ].
Topics: Antiparkinson Agents; Apomorphine; Dyskinesias; Humans; Parkinson Disease | 2000 |
4 trial(s) available for apomorphine and Abnormal Movements
| Article | Year |
|---|---|
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Topics: Administration, Sublingual; Adult; Aged; Antiparkinson Agents; Apomorphine; Canada; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome; United States | 2020 |
Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Deep Brain Stimulation; Dyskinesias; Female; Humans; Hypodermoclysis; Infusions, Parenteral; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 2012 |
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesias; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Prospective Studies; Self-Assessment; Statistics, Nonparametric | 2005 |
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation.
Topics: Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Dyskinesias; Electric Stimulation Therapy; Female; Functional Laterality; Globus Pallidus; Humans; Male; Middle Aged; Parkinson Disease | 2001 |
14 other study(ies) available for apomorphine and Abnormal Movements
| Article | Year |
|---|---|
The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis.
Topics: Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dyskinesias; Female; Humans; Impulsive Behavior; Male; Parkinson Disease; Prevalence; Retrospective Studies | 2022 |
Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience.
Topics: Antiparkinson Agents; Apomorphine; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Cognition Disorders; Cohort Studies; Dopamine Agonists; Dyskinesias; Female; Humans; Infusions, Subcutaneous; Male; Middle Aged; Parkinson Disease; Sensation Disorders; Severity of Illness Index; Treatment Outcome | 2017 |
A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.
Topics: alpha-Synuclein; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Humans; Locomotion; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Nerve Tissue Proteins; Parkinsonian Disorders; Phosphorylation; Point Mutation; Post-Synaptic Density; Prions; Promoter Regions, Genetic; Protein Processing, Post-Translational; Stereotyped Behavior; Substantia Nigra; Transgenes | 2015 |
EMG activity and neuronal activity in the internal globus pallidus (GPi) and their interaction are different between hemiballismus and apomorphine induced dyskinesias of Parkinson's disease (AID).
Topics: Action Potentials; Adult; Aged; Apomorphine; Arm; Dyskinesias; Electromyography; Globus Pallidus; Humans; Intraoperative Period; Male; Microelectrodes; Movement; Muscle, Skeletal; Parkinson Disease | 2015 |
Electro-acupuncture stimulation improves motor disorders in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; Dopamine; Dyskinesias; Electroacupuncture; Enkephalins; Glutamate Decarboxylase; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Parkinsonian Disorders; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Substance P; Tyrosine 3-Monooxygenase | 2009 |
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Postoperative Complications; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Sympatholytics | 2011 |
Subthalamic activity during diphasic dyskinesias in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Cohort Studies; Deep Brain Stimulation; Disease Progression; Dyskinesias; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Theta Rhythm | 2012 |
[RESEARCH ON CERTAIN DIGESTIVE DYSKINESIAS AND FUNCTIONAL DISORDERS].
Topics: Antiemetics; Apomorphine; Cobalt Isotopes; Cyclophosphamide; Digitalis Glycosides; Dyskinesias; Dyspepsia; Esophageal Achalasia; Fluorouracil; Gastroenterology; Mechlorethamine; Pharmacology; Postgastrectomy Syndromes; Pyloric Stenosis; Radiation Injuries; Radioisotope Teletherapy; Research; Thiotepa; Toxicology; Vinblastine; Vomiting | 1964 |
A specific for relief of pain in bilary dyskinesia.
Topics: Apomorphine; Dyskinesias; Humans; Pain | 1960 |
The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Benzamides; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Female; Forelimb; Immunohistochemistry; Levodopa; Medial Forebrain Bundle; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Presynaptic | 2003 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Implants; Dyskinesias; Inflammation; Injections, Subcutaneous; Macaca fascicularis; Male; Movement; Parkinsonian Disorders; Polyvinyls; Recovery of Function; Steroids | 2005 |
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Topics: Aged; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Nitriles; Parkinson Disease | 2001 |